Momenta Pharmaceuticals (MNTA) Releases Earnings Results, Misses Expectations By $-0.01 EPS

Momenta Pharmaceuticals (MNTA) reported quarterly earnings results on Tuesday, May-3-2016. The company reported $-0.35 earnings per share for the quarter, missing the analyst consensus estimate by $-0.01. Analysts had a consensus of $-0.34. The company posted revenue of $19.90 million in the period, compared to analysts expectations of $26.74 million. The company’s revenue was up 132.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.40 EPS.

Momenta Pharmaceuticals opened for trading at $9.58 and hit $9.78 on the upside on Monday, eventually ending the session at $9.76, with a gain of 2.63% or 0.25 points. The heightened volatility saw the trading volume jump to 6,46,059 shares. Company has a market cap of $675 M.

In a different news, on Apr 19, 2016, John E Bishop (Senior VP, Pharmaceutical Scie) sold 2,843 shares at $9.57 per share price. According to the SEC, on Feb 24, 2016, Craig A Wheeler (President) sold 1,688 shares at $9.95 per share price. On Feb 24, 2016, Richard P Shea (SVP, CFO) sold 227 shares at $9.65 per share price, according to the Form-4 filing with the securities and exchange commission.

Momenta Pharmaceuticals Inc. (Momenta) is a biotechnology company focused on developing generic versions of drugs biosimilars and therapeutics for oncology and autoimmune disease. The Company has three product areas: Complex Generics Biosimilars and Novel Therapeutics. The Company’s product a generic version of Lovenox (enoxaparin sodium injection) was approved by the United States Food and Drug Administration. The Company is developing Complex Generics such as Enoxaparin Sodium Injection and M356. The Company is developing Bosimilars including M923 and M834. The Company is developing Novel Therapeutics including Necuparanib. The Company is developing M356 as a generic version of Copaxone. The Company is developing M923 a biosimilar of HUMIRA. The Company is developing M834 as a biosimilar of ORENCIA.

Momenta Pharmaceuticals

Leave a Reply

Momenta Pharmaceuticals - Is it time to Sell?

Top Brokerage Firms are advising their investors on Momenta Pharmaceuticals. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.